ClinicalTrials.gg
TerminatedNCT00475657Updated May 29, 2009Results posted

Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer

A Phase 2 interventional study of pemetrexed and cisplatin in Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Terminated at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-05-29.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated due to lack of efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies testing cisplatin in Small Cell Lung Carcinoma — 2 open to participants now, 2 under way, none of them phase 3. Cisplatin · Small Cell Lung Carcinoma.

Enrollment
30th of 32
5 · median 62
Started
2007
with 2 others
Phase 2
15 of 33
2 open now
Registered
19th of 33
by date
Lead sponsor
2 of 33
Eli Lilly and Company

Among the 33 studies testing cisplatin in Small Cell Lung Carcinoma, this one is the 30th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2007, is one of 15 in phase 2, and was the 19th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 33 studies testing cisplatin in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing cisplatin in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to determine if cisplatin and pemetrexed are effective in the treatment of patients with Small Cell Lung Cancer, extended disease.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic diagnosis of Small Cell Lung Cancer (SCLC).
  • Functional stage from 0 to 2 of the functional scale
  • No previous systemic chemotherapy, immunotherapy or biologic therapy for SCLC.
  • Previous bone marrow radiotherapy less than 25% is allowed.
  • There must be at least one that complies with the solid tumor response evaluation criteria.
  • Appropriate organic function.
  • estimated at 12 weeks minimum.
  • Females must be surgically sterile, or follow approved medical methods during the treatment period and 6 months afterwards. Males must be surgically sterile or use a contraceptive method during the treatment period and during 6 months after treatment.
  • The patient must be compliant and located close to the trial area for appropriate follow-up.
  • The patient or his/her legal representative must sign an document.
  • Patients must be at least 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Having received treatment for the last 30 days with a drug that has not obtained regulatory approval.
  • Having participated in a previous pemetrexed trial.
  • Mixed histologic diagnosis of SCLC and NSCLC.
  • Concurrent illness.
  • Having an active infection.
  • Severe cardiac disease.
  • Having received recently or concurrently a vaccine against yellow fever.
  • Having suffered a previous malignant process other than SCLC.
  • Central nervous system (CNS) require concurrent corticoid therapy. Treated and stable are allowed.
  • fluid accumulation in the third space.
  • Significant weight loss (greater than or equal to 10%) within 6 weeks prior to trial inclusion.
  • Concurrent administration of any other anti-tumor treatment.
  • Severe renal failure.
  • Unable to discontinue administration of non-steroidal anti-inflammatory (NSAIDS) agents.
  • Inability or unwillingness to take folic acid and vitamin B12 supplements.
  • Inability to take corticoids.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    A

    Drug: pemetrexed · Drug: cisplatin

Interventions

  • 500 mg/m2, intravenous (IV), every 21 days x 6 cycles

    Also known as: LY231514, Alimta

  • 75 mg/m2, intravenous (IV), every 21 days x 6 cycles

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Trial terminated - results not analyzed

    Time frame: baseline to measured progressive disease

Secondary outcomes

  1. Overall Survival

    Trial terminated - results not analyzed

    Time frame: baseline to date of death from any cause

  2. Progression Free Survival

    Trial terminated - results not analyzed

    Time frame: baseline to measured progressive disease

  3. Duration of Response

    Trial terminated - results not analyzed

    Time frame: time of response to progressive disease

  4. Stable Disease Rate

    Trial terminated - results not analyzed

    Time frame: baseline to measured progressive disease

07

Results

Posted May 25, 2009
Limitations and caveats
On the advice of an independent monitoring board, this trial was stopped early due to lack of efficacy of the combination pemetrexed/carboplatin for small cell lung cancer.

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Cisplatin
Started5
Completed1
Not completed4
Withdrew: Death1
Withdrew: Sponsor's decision3

Outcome measures

PrimaryOverall Response Rate

Trial terminated - results not analyzed

Time frame:
baseline to measured progressive disease
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryOverall Survival

Trial terminated - results not analyzed

Time frame:
baseline to date of death from any cause
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryProgression Free Survival

Trial terminated - results not analyzed

Time frame:
baseline to measured progressive disease
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryDuration of Response

Trial terminated - results not analyzed

Time frame:
time of response to progressive disease
Reported as:
Mean · months

No measurements were reported for this outcome.

SecondaryStable Disease Rate

Trial terminated - results not analyzed

Time frame:
baseline to measured progressive disease
Reported as:
Number · participants

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Cisplatin———
Most frequent serious events
Most frequent serious events
EventPemetrexed + Cisplatin
DiarrhoeaGastrointestinal disorders1/5
Renal failure acuteRenal and urinary disorders1/5
PyrexiaGeneral disorders1/5
DysphagiaGastrointestinal disorders1/5
Most frequent other events
Most frequent other events
EventPemetrexed + Cisplatin
AnaemiaBlood and lymphatic system disorders1/5
AstheniaGeneral disorders1/5
Gamma-glutamyltransferase increasedInvestigations1/5
Blood creatine increasedInvestigations1/5
LeukopeniaBlood and lymphatic system disorders1/5
LymphopeniaBlood and lymphatic system disorders1/5
NauseaGastrointestinal disorders1/5
HypokalaemiaMetabolism and nutrition disorders1/5
Inappropriate antidiuretic hormone secretionEndocrine disorders1/5

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed + Cisplatin
Mean66.6 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Cisplatin
Female0
Male5
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Cisplatin
Spain5
Race/Ethnicity
Race/Ethnicity(participants)Pemetrexed + Cisplatin
Caucasian5
Height
Height(centimeters)Pemetrexed + Cisplatin
Mean163.9 ± 4.2
Weight
Weight(kilograms)Pemetrexed + Cisplatin
Mean76.0 ± 5.9
08

Study locations

6 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ferrol, 15405, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Coruña, 15002, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lugo, 27004, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ourense, 15009, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santiago de Compostela, 15706, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vigo, 36211, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2007
First posted
May 21, 2007
Start
Oct 2007
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
May 25, 2009
Last update
May 29, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00475657
First posted
May 21, 2007
Start date
Oct 2007
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
May 25, 2009
Last update
May 29, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion